Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 18.14% is 14% below its 5-year average of 21.16%, near the low end of its 5-year range (7.68%–45.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.45% below its 12-month average of 19.60%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 18.14%.
RETURN ON EQUITY (ROE)
18.14%
RETURN ON EQUITY (ROE) AVG TTM
19.60%
RETURN ON EQUITY (ROE) AVG 3Y
22.40%
RETURN ON EQUITY (ROE) AVG 5Y
21.16%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.45%
CURRENT VS 3Y AVG
-19.02%
CURRENT VS 5Y AVG
-14.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 623 covered companies
CURRENT VS SECTOR MEDIAN
+145.13%
vs the sector median at left
Harmony Biosciences Holdings, Inc.
Market Cap
$2.31B
Return on Equity (ROE)
18.14%
TTM Avg
19.60%
3Y Avg
22.40%
5Y Avg
21.16%
Market Cap
$2.29B
Return on Equity (ROE)
-37.82%
TTM Avg
-53.05%
3Y Avg
-23.57%
5Y Avg
8.38%
Market Cap
$2.36B
Return on Equity (ROE)
71.04%
TTM Avg
-161.38%
3Y Avg
-133.53%
5Y Avg
-111.86%
Market Cap
$2.37B
Return on Equity (ROE)
-84.78%
TTM Avg
-42.91%
3Y Avg
-54.25%
5Y Avg
-44.36%
Market Cap
$2.39B
Return on Equity (ROE)
41.39%
TTM Avg
43.71%
3Y Avg
5.79%
5Y Avg
-18.90%
Market Cap
$2.40B
Return on Equity (ROE)
-4.88%
TTM Avg
-20.16%
3Y Avg
-52.49%
5Y Avg
-49.61%
Market Cap
$2.43B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
9.38%
5Y Avg
9.38%
Market Cap
$2.43B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.46B
Return on Equity (ROE)
-38.17%
TTM Avg
-26.66%
3Y Avg
-25.50%
5Y Avg
23.47%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | $2.31B | 18.14% | 19.60% | 22.40% | 21.16% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.29B | -37.82% | -53.05% | -23.57% | 8.38% |
| Liquidia Corporation (LQDA)vs › | $2.36B | 71.04% | -161.38% | -133.53% | -111.86% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.37B | -84.78% | -42.91% | -54.25% | -44.36% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.39B | 41.39% | 43.71% | 5.79% | -18.90% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -4.88% | -20.16% | -52.49% | -49.61% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.43B | N/A | 9.38% | 9.38% | 9.38% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -56.71% | -50.91% | -55.48% | -35.68% |
| Disc Medicine, Inc. (IRON)vs › | $2.46B | -38.17% | -26.66% | -25.50% | 23.47% |
| Pharvaris N.V. (PHVS)vs › | $2.15B | -57.96% | -57.45% | -48.08% | -40.68% |
ROE
18.1%
ROA
13.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 18.14% |
| 2026-03-31 | 16.00% |
| 2025-12-31 | 18.24% |
| 2025-09-30 | 22.23% |
| 2025-06-30 | 23.40% |
| 2025-03-31 | 21.20% |
| 2024-12-31 | 22.07% |
| 2024-09-30 | 20.55% |
| 2024-06-30 | 21.35% |
| 2024-03-31 | 26.72% |
| 2023-12-31 | 27.59% |
| 2023-09-30 | 31.32% |
| 2023-06-30 | 41.27% |
| 2023-03-31 | 42.77% |
| 2022-12-31 | 45.05% |
| 2022-09-30 | 45.27% |
| 2022-06-30 | 23.57% |
| 2022-03-31 | 22.70% |
| 2021-12-31 | 18.55% |
| 2021-09-30 | 7.68% |
| 2021-06-30 | 18.34% |
| 2021-03-31 | 8.40% |
| 2020-12-31 | -38.02% |
| 2020-09-30 | -77.40% |
